While the dollar amount is small, the fact that both the CEO and a director are buying shares at current levels may indicate confidence ahead of potential catalysts. Traders should monitor for follow-on buying or upcoming clinical/data readouts.
ONCY drugs
ONCY drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 11 $1.01entry
- T+1 · 8mo ago −4.95%α −3.47% · $0.9600
- T+5 · 8mo ago −4.95%α −2.76% · $0.9600
- T+20 · 7mo ago +2.97%α +2.45% · $1.04
- T+60 · 6mo ago −12.87%α −24.39% · $0.8800
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two corporate insiders at Oncolytics Biotech purchased shares in the open market within the past week, including CEO Kelly Jared and Director James T. Parsons, signaling confidence in the company. The total value of purchases was $15,148, a small but notable insider buying cluster.
Key Financial Metrics
Key Facts
- CEO Kelly Jared purchased 5,050 shares at $0.96 per share for a total of $4,848 in open-market transactions.
- Director James T. Parsons purchased 10,000 shares at $1.03 per share for a total of $10,300 in open-market transactions.
- All transactions were open-market purchases (P), indicating actual cash investment by insiders.
- Total insider buying in the past 7 days: $15,148 across 2 transactions.
Financial Impact
$15,148 in total open-market purchases, representing approximately 0.015% of the company's $103M market cap.
Risk Factors
- The total transaction value is low relative to market cap, limiting immediate market impact.
- Biotech stocks like ONCY are highly sensitive to clinical trial outcomes and regulatory developments, which could override insider sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (2 trades, 7d window) | cluster-ONCY-1773403240908 |
Track record
32 reports on ONCY
2 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 6 of 11 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers